What the FDA labels say about taking them together
Colchicine and darunavir
Colchicine's FDA label (Lodoco) of August 13, 2026 names darunavir in its drug interactions section, and darunavir's label names colchicine too. The colchicine label: “Significant increases in colchicine plasma levels.”
Check it at the source: the colchicine FDA label on DailyMed (effective July 22, 2025, Aurobindo Pharma Limited); the darunavir FDA label on DailyMed (effective August 29, 2025, Janssen Products LP).
What does the colchicine label say about darunavir?
Lodoco label (AGEPHA Pharma USA, LLC, August 13, 2026), drug interactionsDrug class: Strong CYP3A4 Inhibitors † atazanavir clarithromycin darunavir/ritonavir indinavir itraconazole ketoconazole lopinavir/ritonavir nefazodone nelfinavir ritonavir saquinavir telithromycin tipranavir/ritonavir; Outcome/effect: Significant increases in colchicine plasma levels [see Clinical Pharmacology (12.3)].; Clinical comment: Concomitant use of LODOCO with strong CYP3A4 inhibitors is contraindicated [see Contraindications (4)].
Source: FDA drug label (Lodoco, NDA215727), AGEPHA Pharma USA, LLC, effective August 13, 2026 (SPL set ff06d68f-d65f-d097-e053-6294a90a7e5f), via openFDA
Source: FDA drug label (Colchicine), Aurobindo Pharma Limited, effective July 22, 2025 (SPL set dd93a40f-92ab-47ac-9083-b8a7a0b18ad6), via openFDA; the full label on DailyMed
What does the darunavir label say about colchicine?
Darunavir label, contraindicationsAlpha 1-adrenoreceptor antagonist: alfuzosin Anti-gout: colchicine, in patients with renal and/or hepatic impairment Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Cardiac Disorders: dronedarone, ivabradine, ranolazine Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine Herbal product:
Darunavir label, drug interactionsConcomitant Drug Class Drug Name Examples: Anti-gout: colchicine; Effect on Concentration of Darunavir Or Concomitant Drug: ↑ colchicine; Clinical Comment: Co-administration is contraindicated in patients with renal and/or hepatic impairment due to potential for serious and/or life-threatening reactions. For patients without renal or hepatic impairment: Treatment of gout-flares – co-administration of colchicine in patients on PREZISTA/ritonavir: 0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Treatment course to be repeated no earlier than 3 days. …
Source: FDA drug label (PREZISTA), Janssen Products LP, effective August 29, 2025 (SPL set 814301f9-c990-46a5-b481-2879a521a16f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Colchicine | Darunavir | |
|---|---|---|
| Labeled for | Gout | HIV |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.122 per tablet 0.6 mg tablet | $1.16 per tablet 600 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once